{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:40Z","timestamp":1791993940920,"version":"4.4.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>\n                    Fabry disease leads to renal, cardiac, and cerebrovascular manifestations. Phenotypic differences between classically and nonclassically affected patients are evident, but there are few data on the natural course of classical and nonclassical disease in men and women. To describe the natural course of Fabry disease stratified by sex and phenotype, we retrospectively assessed event-free survival from birth to the first clinical visit (before enzyme replacement therapy) in 499 adult patients (mean age 43 years old; 41% men; 57% with the classical phenotype) from three international centers of excellence. We classified patients by phenotype on the basis of characteristic symptoms and enzyme activity. Men and women with classical Fabry disease had higher event rate than did those with nonclassical disease (hazard ratio for men, 5.63, 95% confidence interval, 3.17 to 10.00;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.001; hazard ratio for women, 2.88, 95% confidence interval, 1.54 to 5.40;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.001). Furthermore, men with classical Fabry disease had lower eGFR, higher left ventricular mass, and higher plasma globotriaosylsphingosine concentrations than men with nonclassical Fabry disease or women with either phenotype (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.001). In conclusion, before treatment with enzyme replacement therapy, men with classical Fabry disease had a history of more events than men with nonclassical disease or women with either phenotype; women with classical Fabry disease were more likely to develop complications than women with nonclassical disease. These data may support the development of new guidelines for the monitoring and treatment of Fabry disease and studies on the effects of intervention in subgroups of patients.\n                  <\/jats:p>","DOI":"10.1681\/asn.2016090964","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T21:33:35Z","timestamp":1481837615000},"page":"1631-1641","source":"Crossref","is-referenced-by-count":369,"title":["Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study"],"prefix":"10.1681","volume":"28","author":[{"given":"Maarten","family":"Arends","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Cardiology and Nephrology, Comprehensive Heart Failure Center and Fabry Center for Interdisciplinary Therapy, University Hospital Wuerzburg, Wuerzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Free London National Health Service Foundation Trust and University College London, London, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Free London National Health Service Foundation Trust and University College London, London, United Kingdom and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Oder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Cardiology and Nephrology, Comprehensive Heart Failure Center and Fabry Center for Interdisciplinary Therapy, University Hospital Wuerzburg, Wuerzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver T.","family":"Watkinson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Bartholomew\u2019s Hospital and University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Bartholomew\u2019s Hospital and University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor E.","family":"Linthorst","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits A.","family":"Wijburg","sequence":"additional","affiliation":[{"name":"Pediatrics, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Biegstraaten","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.","family":"Hollak","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,12,15]]},"reference":[{"key":"B1-20230829","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry\u2019s disease: Alpha-galactosidase deficiency.","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"B2-20230829","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency.","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"B4-20230829","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.","volume":"52","author":"Smid","year":"2015","journal-title":"J Med Genet"},{"key":"B5-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: Prevalence of individuals with genetic variants of unknown significance.","volume":"51","author":"van der Tol","year":"2014","journal-title":"J Med Genet"},{"key":"B6-20230829","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"B7-20230829","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X chromosome inactivation in female patients with Fabry disease.","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"B8-20230829","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","article-title":"X-inactivation in Fabry disease.","volume":"505","author":"Elstein","year":"2012","journal-title":"Gene"},{"key":"B9-20230829","doi-asserted-by":"crossref","first-page":"e112188","DOI":"10.1371\/journal.pone.0112188","article-title":"Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.","volume":"9","author":"Mauer","year":"2014","journal-title":"PLoS One"},{"key":"B10-20230829","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: Effectiveness on kidney, heart and brain.","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"B11-20230829","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: Evidence for disease progression towards serious complications.","volume":"274","author":"Weidemann","year":"2013","journal-title":"J Intern Med"},{"key":"B12-20230829","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males.","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"B13-20230829","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course.","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"B14-20230829","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.echo.2009.03.003","article-title":"Age-specific reference intervals for indexed left ventricular mass in children.","volume":"22","author":"Khoury","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"B15-20230829","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1399-0004.2011.01643.x","article-title":"Early cerebral manifestations in a young female with Fabry disease with skewed X-inactivation.","volume":"80","author":"Bouwman","year":"2011","journal-title":"Clin Genet"},{"key":"B16-20230829","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: Consequences for diagnostic assessment.","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"B17-20230829","doi-asserted-by":"crossref","first-page":"e0161330","DOI":"10.1371\/journal.pone.0161330","article-title":"Genotype: A crucial but not unique factor affecting the clinical phenotypes in Fabry disease.","volume":"11","author":"Pan","year":"2016","journal-title":"PLoS One"},{"key":"B18-20230829","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B19-20230829","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetes.","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"key":"B20-20230829","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy.","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"B21-20230829","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: An electrocardiographic, echocardiographic, and autopsy study.","volume":"51","author":"Takenaka","year":"2008","journal-title":"J Cardiol"},{"key":"B22-20230829","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype.","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"B23-20230829","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document.","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"B25-20230829","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease.","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"B26-20230829","doi-asserted-by":"crossref","first-page":"e0124987","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS One"},{"key":"B27-20230829","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpeds.2005.03.004","article-title":"Radiological evidence of early cerebral microvascular disease in young children with Fabry disease.","volume":"147","author":"Cabrera-Salazar","year":"2005","journal-title":"J Pediatr"},{"key":"B28-20230829","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease.","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"B29-20230829","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/8904_2013_222","article-title":"Early cardiac changes in children with anderson-fabry disease.","volume":"11","author":"Havranek","year":"2013","journal-title":"JIMD Rep"},{"key":"B30-20230829","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: Agalsidase-beta enzyme replacement therapy.","volume":"83","author":"Borgwardt","year":"2013","journal-title":"Clin Genet"},{"key":"B31-20230829","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cge.12449","article-title":"Diagnostic dilemmas in Fabry disease: A case series study on GLA mutations of unknown clinical significance.","volume":"88","author":"Smid","year":"2014","journal-title":"Clin Genet"},{"key":"B32-20230829","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/8904_2012_167","article-title":"Questioning the pathogenic role of the GLA p.Ala143Thr \u201cMutation\u201d in Fabry disease: Implications for screening studies and ERT.","volume":"8","author":"Terryn","year":"2013","journal-title":"JIMD Rep"},{"key":"B33-20230829","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma.","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol Genet Metab"},{"key":"B34-20230829","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/humu.10275","article-title":"Fabry disease: Characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.","volume":"22","author":"Yasuda","year":"2003","journal-title":"Hum Mutat"},{"key":"B35-20230829","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2012_154","article-title":"Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry disease.","volume":"7","author":"Niemann","year":"2013","journal-title":"JIMD Rep"},{"key":"B36-20230829","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies.","volume":"114","author":"Ferreira","year":"2014","journal-title":"Mol Genet Metab"},{"key":"B37-20230829","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1756-0500-4-323","article-title":"Genetic screening of Fabry patients with EcoTILLING and HRM technology.","volume":"4","author":"Bono","year":"2011","journal-title":"BMC Res Notes"},{"key":"B38-20230829","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11632","article-title":"An integrated map of genetic variation from 1,092 human genomes.","volume":"491","author":"Abecasis","year":"2012","journal-title":"Nature"},{"key":"B39-20230829","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.","volume":"177","author":"Smid","year":"2014","journal-title":"Int J Cardiol"},{"key":"B40-20230829","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/8904_2014_342","article-title":"Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: Consensus on the approach to diagnosis and follow-up.","volume":"17","author":"van der Tol","year":"2014","journal-title":"JIMD Rep"},{"key":"B42-20230829","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B43-20230829","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: A report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"B45-20230829","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00004728-200605000-00013","article-title":"Left ventricular papillary muscle mass: Relationship to left ventricular mass and volumes by magnetic resonance imaging.","volume":"30","author":"Vogel-Claussen","year":"2006","journal-title":"J Comput Assist Tomogr"},{"key":"B46-20230829","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12471-016-0805-y","article-title":"Impact of the papillary muscles on cardiac magnetic resonance image analysis of important left ventricular parameters in hypertrophic cardiomyopathy.","volume":"24","author":"Gommans","year":"2016","journal-title":"Neth Heart J"},{"key":"B47-20230829","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry.","volume":"59","author":"Gold","year":"2013","journal-title":"Clin Chem"},{"key":"B48-20230829","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.csda.2011.02.014","article-title":"Sharpening Wald-type inference in robust regression for small samples.","volume":"55","author":"Koller","year":"2011","journal-title":"Comput Stat Data Anal"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201705000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:28:34Z","timestamp":1786130914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201705000-00033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2016090964","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}